Molina Healthcare Prior Authorization Lookup
- Molina Healthcare timely filing
- Molina Healthcare coverage criteria
- Molina Healthcare contact directory
- All Molina Healthcare policy updates
Latest Molina Healthcare prior authorization updates25
- Prior AuthClinical/Medical PolicyEff. 2026-10-01Kentucky Medicaid Pharmacy Prior Authorization CriteriaPrior authorization criteria for pharmacy and specialty drug categories covered under Molina Healthcare’s Kentucky Medicaid program.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-01Kesimpta (ofatumumab), IL Medicaid OnlyMolina Healthcare IL Medicaid coverage and prior authorization requirements for Kesimpta (ofatumumab) in adults with relapsing forms of multiple sclerosis, including approval criteria, documentation, dosing, administration setting, and contraindications.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Acid Sphingomyelinase Deficiency (ASMD) — Xenpozyme CoveragePrior authorization coverage of intravenous Xenpozyme (olipudase alfa-rpcp) for adult and pediatric members with acid sphingomyelinase deficiency, limited to non-central nervous system manifestations and subject to diagnostic, clinical, specialist, and dosing documentation requirements.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Adzynma Coverage for Congenital Thrombotic Thrombocytopenic PurpuraThis policy governs coverage and prior authorization for intravenous Adzynma as prophylactic or on-demand enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura in adult and pediatric members. Coverage requires documented diagnosis, laboratory and genetic confirmation, treatment planning, specialist involvement, and response at renewal.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Alpha-Mannosidosis (AM): Lamzede (velmanase alfa-tycv) Coverage CriteriaPrior authorization and coverage criteria for intravenous Lamzede in adult and pediatric members with alpha-mannosidosis and non-central nervous system manifestations.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Chronic Hyperammonemia: Ravicti (Glycerol Phenylbutyrate)Prior authorization and continued coverage of oral Ravicti for chronic hyperammonemia caused by a qualifying urea cycle disorder, subject to diagnostic confirmation, required prior therapies, specialist involvement, and evidence of treatment response and adherence.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Classic Congenital Adrenal Hyperplasia (CAH): Crinecerfont CoverageThis policy governs prior authorization and coverage of oral crinecerfont (Crenessity) for adults and pediatric patients at least 4 years old with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Coverage requires documented adjunctive glucocorticoid use, stable supraphysiologic glucocorticoid dosing, applicable formulation criteria, and involvement by a board-certified endocrinologist.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Ebglyss (lebrikizumab) Coverage CriteriaThis policy governs prior authorization and continuation coverage for Ebglyss (lebrikizumab-lbkz) in members aged 12 years and older with moderate-to-severe atopic dermatitis, including clinical eligibility, treatment history, documentation, dosing, administration, and Illinois-specific requirements.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Forzinity (elamipretide) for Barth syndromeThis policy governs prior authorization coverage for Forzinity (elamipretide), a once-daily subcutaneous treatment for patients with genetically confirmed Barth syndrome. It establishes initial and continuation criteria, prescriber and administration requirements, exclusions, and documentation needed for coverage.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Gamifant (emapalumab-lzsg) Coverage PolicyThis policy governs Molina Healthcare coverage and prior authorization for Gamifant (emapalumab-lzsg) used to treat primary or secondary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS). Coverage is subject to member benefit eligibility, clinical criteria, required documentation, prescriber qualifications, and authorization duration limits.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Hepcludex (bulevirtide-gmod) Coverage CriteriaThis policy governs prior authorization coverage of Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis D virus infection and defines documentation, clinical eligibility, prescriber, dosing, administration, and continuation requirements.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Kanuma (sebelipase alfa) Coverage CriteriaCoverage and prior authorization requirements for intravenous Kanuma (sebelipase alfa) in members with lysosomal acid lipase deficiency, including Wolman disease and cholesteryl ester storage disease.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Keveyis (dichlorphenamide) Coverage CriteriaPrior authorization and pharmacy benefit coverage for oral dichlorphenamide products used to treat primary hyperkalemic or hypokalemic periodic paralysis and related variants, subject to clinical, prescriber, age, quantity, and safety requirements.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Mepsevii (vestronidase alfa-vjbk) Coverage CriteriaPrior authorization and coverage criteria for intravenous Mepsevii in members with Mucopolysaccharidosis VII (MPS VII, Sly syndrome), including therapy criteria, documentation, dosing, prescriber, age, duration, and site-of-care requirements.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Mepsevii (vestronidase alfa-vjbk) for Mucopolysaccharidosis VIICoverage and prior authorization for intravenous Mepsevii in pediatric and adult members with Mucopolysaccharidosis VII, requiring diagnostic confirmation, qualifying disease manifestations, baseline assessments, qualified prescribing, and response or stability for reauthorization.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Miglustat Coverage for Type 1 Gaucher Disease and Niemann-Pick Disease Type CPrior authorization and coverage criteria for oral miglustat products in adults with mild-to-moderate Type 1 Gaucher disease when enzyme replacement therapy is not a therapeutic option, and in members with Niemann-Pick disease type C with qualifying neurologic, psychiatric, or cognitive manifestations.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Molybdenum Cofactor Deficiency (MoCD) Type A — Nulibry (fosdenopterin) Coverage CriteriaThis policy governs prior authorization and coverage of intravenous Nulibry (fosdenopterin) for members with confirmed or presumptive Molybdenum Cofactor Deficiency Type A. It establishes diagnostic, documentation, prescriber, dosing, continuation, administration-site, and duration-of-approval requirements.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Naglazyme (galsulfase) Coverage CriteriaThis policy governs prior authorization and coverage criteria for intravenous Naglazyme (galsulfase) for members with Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome). Coverage depends on benefit eligibility, medical necessity, required documentation, specialist involvement, age, dosing, and site-of-care requirements.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Naglazyme (galsulfase) Coverage Criteria for Mucopolysaccharidosis VICoverage and prior authorization requirements for intravenous Naglazyme (galsulfase) to treat mucopolysaccharidosis VI, including clinical, documentation, dosing, and administration requirements.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Nexviazyme Coverage for Late-Onset Pompe DiseaseThis policy governs prior authorization and coverage of intravenous Nexviazyme (avalglucosidase alfa-ngpt) for members aged 1 year and older with documented late-onset Pompe disease. It establishes diagnostic, documentation, prescriber, dosing, continuation, administration-site, and nonconcurrent-therapy requirements.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Nitisinone Coverage for Hereditary Tyrosinemia Type 1 and AlkaptonuriaThis policy governs prior authorization and coverage criteria for oral nitisinone products used for hereditary tyrosinemia type 1 and, for Harliku only, alkaptonuria. It applies to Molina members subject to benefit eligibility, formulary requirements, and documented clinical and monitoring criteria.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Perinatal/Infantile-Onset and Juvenile-Onset HypophosphatasiaThis policy governs coverage and prior authorization for Strensiq (asfotase alfa) for members with documented perinatal/infantile-onset or juvenile-onset hypophosphatasia. It specifies diagnostic, laboratory, radiographic, clinical, prescriber, dosing, continuation, and documentation requirements.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Pombiliti (cipaglucosidase alfa-atga) Coverage for Late-Onset Pompe DiseaseThis policy governs coverage and prior authorization for intravenous Pombiliti used with Opfolda to treat adults with late-onset Pompe disease who weigh at least 40 kg and are not improving on current enzyme replacement therapy.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Tzield (teplizumab-mzwv) Coverage CriteriaThis policy governs Molina Healthcare coverage and prior authorization for intravenous Tzield in members with Stage 2 or recently diagnosed Stage 3 type 1 diabetes. Coverage requires diagnosis-specific clinical documentation, age eligibility, endocrinology prescribing or consultation, and administration in a non-hospital facility-based setting.All Molina Healthcare updates
- Prior AuthClinical/Medical PolicyEff. 2026-09-24Vimizim (elosulfase alfa) Coverage Criteria for MPS IVAThis policy governs Molina Healthcare coverage and prior authorization for Vimizim (elosulfase alfa) to treat mucopolysaccharidosis type IVA (MPS IVA, Morquio A syndrome), subject to benefit eligibility and required clinical documentation.All Molina Healthcare updates
Tool Description
Search Molina Healthcareprior authorization policies by drug name, procedure, or policy title. Results include any policy that mentions prior authorization requirements (drug coverage criteria, imaging guidelines, site-of-service rules) not just documents titled “prior authorization.” Every result links to a full policy page with clinical criteria, covered billing codes, documentation requirements, and effective dates.
Filter by payer, specialty, policy type, or effective year; or search directly for a drug (“Wegovy,” “Ozempic”), a procedure (“MRI,” “knee arthroplasty”), or a policy number.
Coverage spans 110+ payers. Jump straight to the busiest prior-auth publishers: UnitedHealthcare, Cigna, Aetna, Anthem, and Centene. You can also browse the full policy updates feed.
Pair a prior-auth search with the billing code lookup to confirm the CPT or J-code on the claim, the payer lookup for plan footprint, and payer profiles for contacts and coverage context.
FAQ
Prior Authorization by Payer
Go deeper
Explore OpenPayer Data
Prior auth requirements change all the time. Keep up with every payer policy update in the live policy feed, or browse payers with prior authorization policies.
Toolbox
More OpenPayer Tools
- Billing Code LookupSearch CPT, HCPCS, J-codes, DRG, and dental codes by number or procedure name.
- Billing Code Reimbursement RatesBuild a reimbursement rate report across any mix of billing codes and states, comparing commercial payers against Medicare.
- Payer Comparison DashboardPick 2-5 payers to compare market share, premium, and membership by region, all at once.
- Facility Comparison DashboardPick 2-6 hospital facility types (or add a specific hospital) to compare facility count, revenue, net income, and Medicare/Medicaid payer mix by region, all at once.
- Healthcare Provider & Facility LookupFind hospitals and healthcare facilities by name, taxonomy, facility type, ownership, or state.
- Health Insurance Payer LookupSearch national health insurance payers and health plans by name and state presence.
- Provider Taxonomy Code LookupSearch NUCC taxonomy codes by code, specialty, grouping, or classification.
- CPT Modifier LookupSearch CPT modifiers by code or name — descriptions, when to use them, and payer policy context.
- Timely Filing LookupFind payer timely filing policies: claim deadlines, corrected claim windows, and appeal timeframes.
- Coverage Criteria LookupSearch payer coverage criteria and medical necessity requirements by drug, procedure, or payer.
- Payer Contact DirectoryClaims, prior authorization, provider services, and appeals contacts for health insurance payers.
Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.